Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, 12-Week, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Plecanatide (3.0 and 6.0 mg) in Patients With Chronic Idiopathic Constipation (The CIC3 Study)

Trial Profile

A Randomized, 12-Week, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Plecanatide (3.0 and 6.0 mg) in Patients With Chronic Idiopathic Constipation (The CIC3 Study)

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Oct 2018

At a glance

  • Drugs Plecanatide (Primary)
  • Indications Constipation
  • Focus Registrational; Therapeutic Use
  • Acronyms CIC3
  • Sponsors Synergy Pharmaceuticals Inc
  • Most Recent Events

    • 10 Oct 2018 Results (n=883) of a pooled analysis from two phase 3 clinical studies (CIC3 and National CIC3), presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2018.
    • 05 Jun 2018 Results (n=2683) data from two phase 3 clinical studies (CIC3 and National CIC3), presented at the Digestive Disease Week 2018.
    • 24 May 2017 Results (n=2683) assessing impact of Plecanatide on quality of life for patients with chronic idiopathic constipation using patient data from two phase 3 clinical studies (CIC3 and National CIC3), presented at the 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top